FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	or Se	ction 30(h) of	the Investment Company Act of	1340				
Name and Address of Reporting Person*  8 olzon Bradley J PhD  2. Date of Event Requiring Statement (Month/Day/Year) 10/18/2016			3. Issuer Name <b>and</b> Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]					
(Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner		(Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)		
200 SIDNEY STREET	_		Officer (give title below)	Other (spec	App	licable Line)	/Group Filing (Check	
(Street) CAMBRIDGE MA 02139					2		y One Reporting Person y More than One erson	
(City) (State) (Zip)								
	Table I - No	on-Derivat	tive Securities Beneficia	lly Owned				
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ( (Instr. 5)	t (D)   (Insti	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Shares			342,007	D				
Common Shares			239,648	I	See	See footnote <sup>(2)</sup>		
			e Securities Beneficially ants, options, convertibl		s)			
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securi Underlying Derivative Securit		4. Conversion or Exercise	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series A-1 Preferred Shares	(1)	(1)	Common Shares	437,247	(1)	I	See footnote <sup>(2)</sup>	
Series A-1 Preferred Shares	(1)	(1)	Common Shares	2,754	(1)	I	See footnote <sup>(3)</sup>	
Series A-2 Preferred Shares	(1)	(1)	Common Shares	3,100,477	(1)	I	See footnote <sup>(2)</sup>	
Series A-2 Preferred Shares	(1)	(1)	Common Shares	19,524	(1)	I	See footnote <sup>(3)</sup>	
Series A-3 Preferred Shares	(1)	(1)	Common Shares	2,210,417	(1)	I	See footnote <sup>(4)</sup>	
Series A-3 Preferred Shares	(1)					1		
Series A-3 Preferred Shares	(1)	(1)	Common Shares	66,490	(1)	I	See footnote <sup>(5)</sup>	
benes if s fictined shares	(1)	(1)	Common Shares  Common Shares	66,490 168,224	(1)	I	See footnote <sup>(5)</sup> See footnote <sup>(6)</sup>	
Series A-3 Preferred Shares						1		
	(1)	(1)	Common Shares	168,224	(1)	I	See footnote <sup>(6)</sup>	
Series A-3 Preferred Shares	(1)	(1)	Common Shares  Common Shares	168,224 73,704	(1)	I	See footnote <sup>(6)</sup> See footnote <sup>(7)</sup>	
Series A-3 Preferred Shares Series B Preferred Shares	(1)	(1)	Common Shares Common Shares Common Shares	168,224 73,704 231,077	(1) (1) (1)	I I I	See footnote <sup>(6)</sup> See footnote <sup>(7)</sup> See footnote <sup>(2)</sup>	
Series A-3 Preferred Shares Series B Preferred Shares Series B Preferred Shares	(1) (1) (1)	(1) (1) (1) (1)	Common Shares Common Shares Common Shares Common Shares	168,224 73,704 231,077 1,454	(1) (1) (1)	I I	See footnote <sup>(6)</sup> See footnote <sup>(7)</sup> See footnote <sup>(2)</sup> See footnote <sup>(3)</sup>	
Series A-3 Preferred Shares Series B Preferred Shares Series B Preferred Shares Series B Preferred Shares	(1) (1) (1) (1)	(1) (1) (1) (1)	Common Shares Common Shares Common Shares Common Shares Common Shares	168,224 73,704 231,077 1,454 173,167	(1) (1) (1) (1)	I I I	See footnote <sup>(6)</sup> See footnote <sup>(7)</sup> See footnote <sup>(2)</sup> See footnote <sup>(3)</sup> See footnote <sup>(4)</sup>	

## **Explanation of Responses:**

- 1. These securities are convertible on a one-for-one basis at any time into the Issuer's Common Shares at the holder's election and automatically upon the closing of the Issuer's initial public offering into the number of Common Shares shown in column 3 above. These securities do not have an expiration date.
- 2. These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- 3. These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- 4. These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- 5. These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- 6. These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power

over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

7. These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

## Remarks:

<u>/s/ Bradley Bolzon</u>

10/18/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.